Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation

This study explores how a specific genetic mutation of leucine-rich repeat kinase 2 (LRRK2) affects individuals with Parkinson's disease (PD), comparing those with the mutation to others with Parkinson's disease and without the mutation (iPD). Participants will complete positron emission tomography (PET) and magnetic resonance imaging (MRI) brain imaging, cognitive tests, motor tests, sensory tests, and questionnaires. The aims of this study are to compare brain chemicals in LRRK2 PD patients with iPD patients and to correlate brain chemicals with motor and cognitive tests in LRRK2 PD and iPD patients.

NCT Number	NCT07642908
Lead Sponsor	University of Michigan Collaborators: Michael J. Fox Foundation for Parkinson's Research
Conditions	Parkinson Disease
Enrollment	15 participants
Start Date	2025-09-18
Primary Completion	2026-09-17 (estimated)
Study Completion	2026-09-17 (estimated)
Updated on ClinicalTrials.gov	2026-06-11